BE645302A - - Google Patents

Info

Publication number
BE645302A
BE645302A BE645302DA BE645302A BE 645302 A BE645302 A BE 645302A BE 645302D A BE645302D A BE 645302DA BE 645302 A BE645302 A BE 645302A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE645302A publication Critical patent/BE645302A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BE645302D 1961-10-16 1964-03-17 BE645302A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145432A US3149036A (en) 1961-10-16 1961-10-16 Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent

Publications (1)

Publication Number Publication Date
BE645302A true BE645302A (fr) 1964-09-17

Family

ID=22513085

Family Applications (1)

Application Number Title Priority Date Filing Date
BE645302D BE645302A (fr) 1961-10-16 1964-03-17

Country Status (2)

Country Link
US (1) US3149036A (fr)
BE (1) BE645302A (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3531565A (en) * 1969-09-25 1970-09-29 American Cyanamid Co Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acid
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4069313A (en) * 1974-11-19 1978-01-17 Merck & Co., Inc. Water-in-oil adjuvant composition
US4053584A (en) * 1975-02-12 1977-10-11 Recherche Et Industrie Therapeutiques Pre-farrowing pregnant sow piglet colibacillosis vaccines and process for their administration to pregnant sows before farrowing
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
JPS5289612A (en) * 1976-01-22 1977-07-27 Iwao Hishida Granular composite of metallic soap
US4104403A (en) * 1976-12-21 1978-08-01 Witco Chemical Corporation Water-oil emulsions and method of preparing same
US4167560A (en) * 1977-04-12 1979-09-11 Texas Vet Lab, Inc. Polyvalent shipping fever vaccine
DE2966914D1 (en) * 1978-09-14 1984-05-24 Gist Brocades Nv Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4556556A (en) * 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
EP0580778B1 (fr) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Formulations de microemulsions a inversion de phase
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
US20050175584A1 (en) * 2004-01-28 2005-08-11 Paciotti Giulio F. Functionalized colloidal metal compositions and methods
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (fr) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions et procedes de production d'anticorps
BRPI1005670A8 (pt) * 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888180A (fr) * 1900-01-01
US1791878A (en) * 1926-05-17 1931-02-10 Strauch Clauss Burkart Water-oil emulsion and suspension for medical purposes and process for manufacturing the same
US2055083A (en) * 1932-07-13 1936-09-22 Winthrop Chem Co Inc Pharmaceutical preparation
US2154432A (en) * 1936-04-27 1939-04-18 J C Shay Inc Therapeutic colloid
US2529461A (en) * 1949-04-30 1950-11-07 Sharp & Dohme Inc Emulsions
US2675343A (en) * 1951-12-18 1954-04-13 Smith Kline French Lab Emulsion-forming liquid product
US2819199A (en) * 1953-10-27 1958-01-07 Schenley Lab Inc Stable injectable fat emulsions and process of producing same
GB759577A (en) * 1953-12-17 1956-10-17 Bristol Lab Inc Oral therapeutic preparations containing coconut oil
US2988484A (en) * 1956-07-24 1961-06-13 Drew & Co Inc E F Alcohol soluble pharmaceutical compositions
US3083142A (en) * 1958-02-27 1963-03-26 Glaxo Group Ltd Improved swine erysipelas vaccine
US2981658A (en) * 1958-07-07 1961-04-25 Julius S Youngner Lipid purification and concentration of viruses and vaccines therefrom
US2972565A (en) * 1958-04-04 1961-02-21 Univ Tennessee Res Corp Fat composition
US3099601A (en) * 1959-10-02 1963-07-30 Anchor Serum Company Bacterin in aqueous polyethylene, mineral oil emulsion
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Also Published As

Publication number Publication date
US3149036A (en) 1964-09-15

Similar Documents

Publication Publication Date Title
AT224007B (fr)
BE568568A (fr)
BE602240A (fr)
BE645302A (fr)
BE641175A (fr)
BE626578A (fr)
BE625188A (fr)
BE622316A (fr)
BE622217A (fr)
BE12203A (fr)
BE617408A (fr)
BE616096A (fr)
BE164003A (fr)
BE396226A (fr)
BE458606A (fr)
BE464928A (fr)
BE614594A (fr)
BE469342A (fr)
BE472265A (fr)
BE475425A (fr)
BE475477A (fr)
BE614048A (fr)
BE613384A (fr)
BE609395A (fr)
BE476407A (fr)